1. Home
  2. BEAM vs ABM Comparison

BEAM vs ABM Comparison

Compare BEAM & ABM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

SELL

Current Price

$23.29

Market Cap

2.6B

Sector

Health Care

ML Signal

SELL

Logo ABM Industries Incorporated

ABM

ABM Industries Incorporated

SELL

Current Price

$51.19

Market Cap

2.8B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
BEAM
ABM
Founded
2017
1909
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Diversified Commercial Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.8B
IPO Year
2019
1994

Fundamental Metrics

Financial Performance
Metric
BEAM
ABM
Price
$23.29
$51.19
Analyst Decision
Strong Buy
Buy
Analyst Count
15
8
Target Price
$52.15
★ $55.93
AVG Volume (30 Days)
★ 1.7M
398.3K
Earning Date
11-03-2026
09-08-2026
Dividend Yield
N/A
★ 2.29%
EPS Growth
82.31
★ 102.34
EPS
N/A
★ 2.20
Revenue
$24,000.00
★ $8,745,900,000.00
Revenue This Year
N/A
$5.43
Revenue Next Year
$29.19
$3.48
P/E Ratio
★ N/A
$23.09
Revenue Growth
★ 33.33
4.62
52 Week Low
$20.23
$36.96
52 Week High
$38.26
$52.10

Technical Indicators

Market Signals
Indicator
BEAM
ABM
Relative Strength Index (RSI) 40.52 64.32
Support Level $22.49 $43.04
Resistance Level $26.72 $51.29
Average True Range (ATR) 1.17 0.94
MACD 0.01 0.17
Stochastic Oscillator 4.89 75.00

Price Performance

Historical Comparison
BEAM
ABM

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About ABM ABM Industries Incorporated

ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.

Share on Social Networks: